secwatch.observer — SEC 8-K summary
======================================

Issuer:     MapLight Therapeutics, Inc. (MPLT)
CIK:        0001770069
Form:       8-K
Filed at:   2026-08-13T20:51:37+00:00
Accession:  0001193125-26-349490
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 2.02, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MapLight raises $150M PIPE, Q2 net loss $60.2M; ZEPHYR Phase 2 met primary endpoint
--------------------------------------------------------------------------------

- $150M PIPE: 9,197,887 shares at $11.38/share plus pre-funded warrants for 3,983,168 shares; closes Aug 14, 2026
- Q2 2026 net loss $60.2M vs $29.8M YoY; R&D $53.4M vs $26.8M; cash $351.3M at June 30, 2026
- Phase 2 ZEPHYR trial of ML-007C-MA in schizophrenia met primary endpoint; Phase 3 ZEPHYR-2 topline expected 2028
- Phase 2 VISTA trial in Alzheimer's disease psychosis enrolling; topline expected H2 2027; Fast Track designation
- ML-004 Phase 2 IRIS missed primary endpoint in autism; showed improvement in adolescent irritability subgroup

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1770069/000119312526349490/0001193125-26-349490-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1770069/000119312526349490/d48818d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-349490

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer